Global Brain Hemorrhage Market, by Drug Type (Anti-hypertensive Drugs, Anti-convulsants Drugs, Hyperosmostic Drugs, and Others (others include Anti-epileptic Drugs, Anti-pyretic Drugs, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 179.8 million in 2021 and is expected to exhibit a CAGR of 6.0% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Government of various countries such as India, U.S., etc. are focusing on introducing new initiatives to ensure availability of cost effective therapeutics for treatment of brain hemorrhage are expected to drive the growth of the global brain hemorrhage market over the forecast period.
For instance, in August 2019, the government of India added Tenectase (tenecteplase), manufactured by Gennova Biopharmaceuticals Limited, an India based pharmaceutical company to the new guidelines for treatment of brain clots, leading to reduction of treatment cost by almost 50% and also giving a boost to indigenous research.
Global Brain Hemorrhage Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 228 million cases and 4.7 million deaths due to Coronavirus (COVID-19) were reported up till September 19, 2021, across the globe.
The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to hamper the demand and supply in global brain hemorrhage market, as scientists have not established any direct association of COVID-19 with brain hemorrhage. According to a research study published by the Public Health Emergency Collection Journal in October 2020, it was found out that the pooled incidence of intracerebral hemorrhage in COVID-119 patients was only 0.7% thus it can be concluded that intracerebral hemorrhage is an uncommon event in COVID-19 patients.
Browse 35 Market Data Tables and 25 Figures spread through 158 Pages and in-depth TOC on “Brain Hemorrhage Market”- Global Forecast to 2028, by Drug Type (Anti-hypertensive Drugs, Anti-convulsants Drugs, Hyperosmostic Drugs, and Others (others include Anti-epileptic Drugs, Anti-pyretic Drugs, etc.)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global brain hemorrhage market, click the link below:
https://www.coherentmarketinsights.com/market-insight/brain-hemorrhage-market-4659
Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations, mergers, acquisitions, and licensing agreement in order to strengthen their position in the market. For instance, in January 2020, Atnahs Pharma, a U.K. based pharmaceutical company entered into a license agreement with AstraZeneca, a U.K. based pharmaceutical company to own global commercial rights to drugs such as Inderal (propranolol), Tenormin (atenolol), and others. Tenormin (atenolol) is a beta blocker drug which can be used to control high blood pressure during brain hemorrhage.
Key Takeaways of the Global Brain Hemorrhage Market:
- The global brain hemorrhage market is expected to exhibit a CAGR of 6.0% over the forecast period, owing to rising incidence of risk factors associated with brain hemorrhage such as traumatic brain injury. For instance, according to an article published by the Journal of Neurosurgery in April 2018, it is estimated that around 500–800 new cases of traumatic brain injury per 100,000 people are reported every year in the U.S. and New Zealand.
- Among drug type, anti-hypertensive drugs segment is expected to account for largest market share in 2021, owing to its efficiency in treatment of brain hemorrhage. For instance, according to an article published by the Nature Journal in October 2017, it has been found out that intensive blood pressure lowering using anti-hypertensive drugs can result in reduction of hematoma (blood mass) in patients with intracerebral hemorrhage volume less than 15 mL and are taken into immediate medical care within six hours of the incidence of intracerebral hemorrhage.
- Key players operating in the global brain hemorrhage market include Baxter, Oxurion NV, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Boehringer Ingelheim, Novartis AG, Bayer AG, Abbott, Bristol-Myers Squibb, Johnson and Johnson, Neurotech Pharmaceuticals, Inc., Siemens Healthcare GmbH, Novo Nordisk A/S, H. Lundbeck A/S, and Ligand Pharmaceuticals Incorporated
